US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
Executive Summary
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.